Dehydrogenase
Dehydrogenases are enzymes involved in the oxidation-reduction reactions of metabolic pathways, playing a central role in energy production and cellular respiration. These enzymes are crucial for processes such as the citric acid cycle, glycolysis, and fatty acid oxidation. Dehydrogenase inhibitors are important tools in the study of metabolic diseases, cancer, and oxidative stress. At CymitQuimica, we provide a comprehensive selection of dehydrogenase inhibitors to support your research in metabolism, cancer biology, and biochemistry.
Found 302 products of "Dehydrogenase"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
hDHODH-IN-10
hDHODH-IN-10: selective oral inhibitor of hDHODH (IC50: 10.9 nM); blocks cancer cell growth, aids cancer research.Formula:C21H15ClF4N2O4Color and Shape:SolidMolecular weight:470.8PDHK-IN-5
PDHK-IN-5, potent PDHK2 (0.006 μM IC50) & PDHK4 (0.0329 μM IC50) inhibitor, may be explored for cancer and diabetes treatment.Formula:C30H31N5O2Color and Shape:SolidMolecular weight:493.6PHGDH-IN-2
PHGDH-IN-2: potent PHGDH inhibitor, IC50=5.2μM; hinders PHGDH cancer cell growth & serine synthesis in MDA-MB-468.Formula:C22H20N4O3SColor and Shape:SolidMolecular weight:420.48AKR1C3-IN-7
AKR1C3-IN-7 (Compound 13) is an effective and selective AKR1C3 inhibitor (IC50=0.19 μM). AKR1C3-IN-7 has antitumor activity.Formula:C24H20N2O4Color and Shape:SolidMolecular weight:400.43AKR1C3-IN-8
AKR1C3-IN-8 (Compound 5) is an effective and selective AKR1C3 inhibitor (IC50=0.069 μM). AKR1C3-IN-8 has antitumor activity.Formula:C23H20N4O3Color and Shape:SolidMolecular weight:400.43(6S)-CP-470711
CAS:(6S)-CP-470711 (Compound 8) acts as an inhibitor of sorbitol dehydrogenase (SDH) in both humans and rats, exhibiting inhibitory concentrations (IC50) of 19 nM and 27 nM, respectively. Additionally, (6S)-CP-470711 has been shown to ameliorate diabetes in rats induced by Streptozotocin.Formula:C18H26N6O2Color and Shape:SolidMolecular weight:358.44LDHA-IN-5
CAS:LDHA-IN-5 is a novel and potent inhibitor targeting both glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), designed for the treatment of primaryFormula:C27H22FN7O6S3Color and Shape:SolidMolecular weight:655.7HSD17B13-IN-28
CAS:HSD17B13-IN-28 (compound 47) is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), with an IC50 of < 0.1 μM using estradiol as a substrate. HSD17B13-IN-28 plays an important role in nonalcoholic fatty liver diseases (NAFLDs), including NASH (nonalcoholic steatohepatitis) [1].Formula:C23H16Cl2FN3O3Color and Shape:SolidMolecular weight:472.3HSD17B13-IN-17
CAS:HSD17B13-IN-17 (compound 9) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). It demonstrates inhibitory efficacy with IC50 values of ＜0.1 μM for estradiol and ＜1 μM for Leukotriene B3 as substrates. This compound is significant in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].Formula:C20H16ClFN2O3SMolecular weight:418.87HSD17B13-IN-19
CAS:HSD17B13-IN-19 (compound 16) acts as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values under 0.1 μM and under 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is crucial in the treatment of nonalcoholic fatty liver diseases (NAFLDs), such as nonalcoholic steatohepatitis (NASH) [1].Formula:C23H23FN2O4SMolecular weight:442.5HSD17B13-IN-44
CAS:HSD17B13-IN-44 (Compound 23) functions as an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of < 0.1 μM against estradiol. This compound is applicable in the study of liver diseases or metabolic disorders [1].Formula:C18H14FNO5S2Molecular weight:407.4417β-HSD1-IN-1
17β-HSD1-IN-1 (Compound 1) can be used in the non-small cell lung cancer (NSCLC) research.Formula:C21H21NO3Color and Shape:SolidMolecular weight:335.4HSD17B13-IN-30
CAS:HSD17B13-IN-30 (compound 64) serves as a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting an IC 50 value of less than 0.1 μM? with estradiol? as substrates. This compound is significantly implicated in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].Formula:C24H16Cl2F3N3O4Color and Shape:SolidMolecular weight:538.315-epi-PGE1
CAS:15-epi-PGE1 (15R-Prostaglandin E1; 15-Epiprostaglandin E1), a stereoisomer of PGE1, exhibits reduced biological activity [2]. This compound acts as a non-competitive inhibitor of human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH), with an inhibitory concentration 50 (IC50) value of 170 μM [1].Formula:C20H34O5Molecular weight:354.48HSD17B13-IN-32
CAS:HSD17B13-IN-32 (Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤0.1 μM for estradiol. It can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) [1].Formula:C23H15Cl2N5O3Molecular weight:480.3HSD17B13-IN-40
CAS:HSD17B13-IN-40 (compound 6) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM using estradiol as substrates. This compound is significant in the treatment of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].Formula:C23H14Cl2F3N3O3Molecular weight:508.28RORγt/DHODH-IN-3
RORγt/DHODH-IN-3 (compound (S)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.098 μM) and DHODH (IC50: 0.432 μM).RORγt/DHODH-IN-1 hasFormula:C24H26ClF6N3O3SColor and Shape:SolidMolecular weight:585.99Etamicastat hydrochloride
CAS:<p>Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a peripherally selective dopamine beta-hydroxylase inhibitor that reduces hypertension.</p>Formula:C14H16ClF2N3OSPurity:98.54%Color and Shape:SolidMolecular weight:347.81CP-642931
CAS:CP-642931 (Sorbitol dehydrogenase-IN-1) is a sorbitol dehydrogenase inhibitor used in the study of diabetes mellitus and cardiovascular disease.Formula:C17H25N7OPurity:99.67% - >99.99%Color and Shape:SolidMolecular weight:343.43GNE-140 racemate
CAS:GNE-140 is a potent inhibitor of lactate dehydrogenase A (LDHA). GNE-140 is a racemate mixture of (R)-GNE-140 and (S)-GNE-140.Formula:C25H23ClN2O3S2Color and Shape:SolidMolecular weight:499.04
